AI assistant
Sending…
Skye Bioscience, Inc. — Director's Dealing 2024
Oct 31, 2024
34097_dirs_2024-10-30_9bec13b2-075b-40d8-a6b4-2ccf3aaf1243.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Skye Bioscience, Inc. (SKYE)
CIK: 0001516551
Period of Report: 2024-10-28
Reporting Person: Jenkins Annalisa (Director)
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2024-10-28 | Stock Option (Right to Buy) | $5.15 | A | 70000 | Acquired | 2034-10-27 | Common Stock (70000) | Direct |
Footnotes
F1: The stock option vests in equal monthly installments over the one year period beginning October 28, 2024.
More from Skye Bioscience, Inc.
Declaration of Voting Results & Voting Rights Announcements
2026
May 29
Delisting Announcement
2026
May 15
Annual Report
2026
Apr 16
Proxy Solicitation & Information Statement
2026
Apr 16
Board/Management Information
2026
Apr 3
Delisting Announcement
2026
Mar 19
Board/Management Information
2026
Feb 20
Director's Dealing
2026
Feb 10
Director's Dealing
2026
Feb 10
Director's Dealing
2026
Feb 10